Daprodustat is vying to become the first drug in the HIF-PHI inhibitor class to reach the US market, after the FDA rejected two others – FibroGen/AstraZeneca's roxadustat and Akebia's vadadustat ...

GlaxoSmithKline has begun late stage development of its daprodustat, for anaemia associated with chronic kidney disease. GSK said the phase 3 programme included two studies evaluating the safety ...